Treatment of induced oligometastatic disease after partial response to immunochemotherapy in patient with stage IV non-small cell lung cancer and severe toxicity

Hamza Abrar Mughal, Mette T Mouritzen, Zsuzsanna Takacs-Szabó, Weronika Maria Szejniuk*

*Kontaktforfatter

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstract

Treatment of induced oligometastatic disease after partial response to systemic antineoplastic therapy in non-small cell lung cancer (NSCLC) remains controversial. The introduction of immune checkpoint inhibitors (ICIs) has revolutionised the treatment of stage IV NSCLC. While ICI combined with chemotherapy (ChT) leads to longer duration of response and higher response rates compared with ChT alone, it can also cause serious adverse events (AEs) resulting in treatment discontinuation. In case of treatment discontinuation due to AEs after partial response to systemic treatment, surgical treatment of residual disease can be considered as it could lead to complete response. We present a case of a patient with stage IV NSCLC who is currently alive without any signs of cancer after partial response to ICI/ChT followed by surgical removal of residual disease.

OriginalsprogEngelsk
Artikelnummere252590
TidsskriftBMJ Case Reports
Vol/bind15
Udgave nummer12
ISSN1757-790X
DOI
StatusUdgivet - 14 dec. 2022

Bibliografisk note

© BMJ Publishing Group Limited 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Fingeraftryk

Dyk ned i forskningsemnerne om 'Treatment of induced oligometastatic disease after partial response to immunochemotherapy in patient with stage IV non-small cell lung cancer and severe toxicity'. Sammen danner de et unikt fingeraftryk.

Citationsformater